TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05884216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entarik Feeding Tube System
Description: Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Entarik Feeding Tube System without monitoring
Description: Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance.
Study: NCT04793568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon gamma 1b (IMUKIN®)
Description: 100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Interferon gamma 1b placebo
Description: 5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
Study: NCT05462600

Intervention type: OTHER
Intervention: Position change
Description: Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).

Intervention type: OTHER
Intervention: Position change
Description: Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
Study: NCT05731765

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Model
Description: Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Model
Description: Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
Study: NCT04012645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of near infrared-indocyanine green imaging system
Description: Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-application of near infrared-indocyanine green imaging system
Description: Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
Study: NCT05769972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (Parkinson's disease)
Description: This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based cognitive rehabilitation (Parkinson's disease)
Description: This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation (Huntington's disease)
Description: This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
Study: NCT05531669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Project
Description: PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PLAY Project
Description: PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Education
Description: Each study center provides welcome course and parent guide for families with ASD children monthly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Education
Description: Each study center provides welcome course and parent guide for families with ASD children monthly.
Study: NCT04947176

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: 200mg C15:0 once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily
Study: NCT04743180

Intervention type: DEVICE
Intervention: LUMINOR© Paclitaxel eluting balloon
Description: Patients will be treated with the Luminor paclitaxel eluting balloon
Study: NCT05583942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trascutaneous auricular vagus nerve stimulation
Description: The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will appear to function but no electrical stimulation will be delivered.
Study: NCT05731180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identify pathological and not pathological lung sounds
Description: First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
Study: NCT05866055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-973
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-973
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Syrup for oral administration.
Study: NCT05769972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music-therapy (Huntington's disease)
Description: The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory
Study: NCT06515782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Description: In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Description: In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD.
Study: NCT04784689

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: COVID-19 Vaccine
Study: NCT06027437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days.
Study: NCT05987384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Description: D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Description: D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine (Vero Cell) for Human Use
Description: Every participant will receive three doses of rabies vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine (Vero Cell) for Human Use
Description: Every participant will receive three doses of rabies vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine (Vero Cell) for Human Use
Description: Every participant will receive three doses of rabies vaccination.
Study: NCT06126198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
Study: NCT06319833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity interacting with a video
Description: This experimental condition will be implemented five times a week, once per day, over 8 weeks. It will follow a structured format, including seven consecutive 40-second blocks of physical activity. The total video duration will amount to 9 minutes (40 seconds of activity followed by 20 seconds of rest, maintaining a 2:1 work-to-rest ratio). Additionally, participants will engage in 5 minutes of warm-up exercises and 5 minutes of cool-down activities. The experimental condition will consist of 10 videos, each centered around one of five different themes (a different one will be administered every day).
Study: NCT04925440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714® strain
Description: Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing corn-starch and magnesium stearate only.
Study: NCT01775098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: No arms will not be change as the study as been closed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: allopurinol
Description: No arms will not be change as the study as been closed.
Study: NCT06290999

Intervention type: DIAGNOSTIC_TEST
Intervention: multifrequential admittancemetry
Description: Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure.
Study: NCT06524531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed RF Neuromodulation
Description: RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich PRP Injection
Description: Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
Study: NCT05915156

Intervention type: OTHER
Group type: OTHER
Intervention: Post-acute home physiotherapy program
Description: This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
Study: NCT06524531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Alone
Description: Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
Study: NCT01481532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crotoxin
Description: Intra patient dose escalation
Study: NCT05246267

Intervention type: BIOLOGICAL
Intervention: Dupilumab
Description: Standard of care treatment with dupilumab
Study: NCT04699136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 minutes step test (ST6)
Description: Performing a 6 minutes step test at different intervals and comparing with respect with the 6 minutes walk test and cardiac stress test
Study: NCT05355220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Spike Point Therapy (SSPT)
Description: Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Managment
Description: 2 sets of 10 repetitions Bridging, Cat \& cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
Study: NCT05533580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: The experimental group was sedated with remimazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was sedated with propofol.
Study: NCT05646849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connected application
Description: Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
Study: NCT06244901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton
Description: Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal walking
Description: Normal walking for twenty minutes on real-world terrain every day for a week.
Study: NCT06018103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-vision
Description: 8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
Study: NCT05571813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341
Description: A single dose of 1tablets under fasting condition
Study: NCT05741606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium pentaborate pentahydrate
Description: Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium pentaborate pentahydrate
Description: Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium pentaborate pentahydrate
Description: Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium pentaborate pentahydrate
Description: Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium pentaborate pentahydrate
Description: Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT05848063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global hip muscles strengthening exercises
Description: Strengthening exercises will be given to all hip muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip abductors strengthening exercises
Description: Strengthening exercises will be given to hip abductor muscles
Study: NCT05543772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: participant will be given 500 ml normal saline through intravenous access. blood sample will be extracted before and after giving normal saline using same intravenous catheter
Study: NCT05695287

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor

Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: Isoflurane